1. PL02.3.A Survival and T-cell tumor reactivity in patients treated with nivolumab and bevacizumab for recurrent glioblastoma in the clinical trial CA209-9UP. (5th September 2022) Authors: Maarup, S; Skadborg, S; Draghi, A; Borch, A; Hasselbalch, B; Yde, C; Svane, I; Hadrup, S; Christensen, I; Law, I; Skjoeth-Rasmussen, J; Scheie, D; Skovgaard Poulsen, H; Lassen, U Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗